Advanced Oncotherapy PLC Issue of warrants (0661D)
June 16 2023 - 12:23PM
UK Regulatory
TIDMAVO
RNS Number : 0661D
Advanced Oncotherapy PLC
16 June 2023
16 June 2023
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Issue of Warrants
Further to the Company's announcement on 12 December 2022,
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the
next-generation proton therapy system for cancer treatment,
announces that it has, on 14 June 2023, issued warrants to
subscribe for 12,000,000 new Ordinary Shares. The warrants were
issued per the terms of the GBP1,500,000 equity subscription
announced on 12 December 2022.
The warrants have an exercise price of 25 pence per share and
are exercisable until 15 December 2027.
The issue of warrants has been conducted under the Company's
existing share authorities and, notwithstanding the announcement
made by the Company on 12 December 2022, the Company can confirm
that it does not require to convene a general meeting to put in
place new share authorities for this warrant issue.
Following this issuance of warrants the Company has a total of
199,061,873 warrants in issue.
- ENDS -
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
WH Ireland Limited (Financial adviser) Tel: +44 (0) 20 7220 1666
Antonio Bossi / James Bavister AVOPLC@whirelandcm.com
Allenby Capital Limited (Nomad and Joint
Broker)
Nick Athanas / Piers Shimwell (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Amrit Nahal / Matt Butlin (Sales & Corporate
Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEZZGMVNVMGFZM
(END) Dow Jones Newswires
June 16, 2023 13:23 ET (17:23 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024